Afatinib improves progression-free survival in head and neck cancer

Second-line afatinib significantly improves progression-free survival in recurrent or metastatic head and neck cancer, Phase III trial shows

2014-09-27

(Press-News.org) The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

Presented at the ESMO 2014 Congress in Madrid, the Lux-Head & Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median progression-free survival of 2.6 months.

"The improvement in progression-free survival was associated with a significant delayed worsening of symptoms (such as pain, swallowing and global health status) versus chemotherapy. Patients treated with afatinib had less pain over time than patients treated with methotrexate. "These are important outcomes for patients with these conditions," notes study author Dr Jean-Pascal Machiels, a medical oncologist at Institut Roi Albert II, Cliniques Universitaires St. Luc, in Brussels, Belgium.

Recurrent or metastatic squamous cell carcinoma of the head and neck often has a poor outcome, Machiels explains. "This is a poor prognosis population and a disease that does not get enough attention from the scientific community, because this group of patients often has severe co-morbidities and social problems such as alcoholism and tobacco use."

"Frequently these patients have a relapse in the head and neck area. This location is responsible of many symptoms that are difficult to palliate: pain, breath disorder and swallowing difficulties."

Afatinib is a compound that irreversibly blocks the ErbB family of cell surface receptors, which includes epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), HER3 and HER4. Around 90% of squamous cell carcinomas of the head and neck overexpress EGFR.

In the latest trial, researchers aimed to see if inhibiting multiple ErbB receptors simultaneously would improve the clinical efficacy of EGFR-targeted therapy. They studied 483 patients with recurrent or metastatic head and neck squamous cell carcinoma whose cancer had progressed despite treatment with platinum-based therapy. Overall, 322 patients received 40 mg/day oral afatinib and 161 were given 40 mg/m2/week intravenous methotrexate.

The study met its primary endpoint and afatinib significantly improved progression-free survival versus methotrexate, Machiels said. "Afatinib improved progression-free survival and delayed worsening of symptoms, and it is the first tyrosine kinase inhibitor to demonstrate a significant benefit in this disease."

The toxicity profile was acceptable and manageable with afatinib : the most frequent grade 3/4 drug-related adverse events were rash/acne (9.7%) and diarrhea (9.4%). Less treatment-related dose reductions, discontinuations and fatal events were seen with afatinib.

"We are pleased with the results because we showed a benefit, although modest, in a very well-designed controlled trial," Machiels says. "The difference of this trial compared to the others performed in the same setting is that it was a homogenous population. It sets a kind of baseline design that could be used to design further trials."

The trial was not able to demonstrate that afatinib improves survival. "Many potential reasons could explain why we were not able to demonstrate a survival benefit," Machiels says. "It could be simply because afatinib does not improve survival. However, 50% of the patients in both arms received subsequent therapies that could have influenced the survival benefit, for example a significant number of patients received subsequent anti-EGFR therapies in the methotrexate arm."

Future studies should focus on understanding which patient groups derive a clinically meaningful benefit from afatinib, the researchers says. They hope to provide further molecular insights and hypotheses to identify patients who benefit.

"We should hope that based on the new molecular data that is becoming available and through advances in the understanding of the molecular biology of this disease, some new treatments will be investigated in a near future." INFORMATION: END

ELSE PRESS RELEASES FROM THIS DATE:

Rolapitant reduces nausea and vomiting in Phase III trial

2014-09-27

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain. Dr Martin Chasen, lead author and medical director, Palliative Care, Ottawa Hospital Cancer Centre, Canada, said: "This agent makes a significant difference in the way people tolerate their chemotherapy. Patients experienced no loss in quality of life and, in fact, many saw meaningful improvements. One of the patients in the rolapitant cohort reported that ...

Countries must work together to stop organ traffickers, says researcher

2014-09-27

The author of new research into organ trafficking has called for a concerted international effort to confront the problem. Dr Ana Manzano, of the School of Sociology and Social Policy at the University of Leeds, says a combination of factors means nobody knows definitively how many organs are being traded across the world. She said: "Unless these issues are addressed and countries work together to take firm action against the traffickers, more people who have their organs trafficked will die. "Even in the UK, although the World Health Organization has identified us ...

Smoke still rising from King Fire in California

2014-09-26

Over 96,004 acres have been burned by the King Fire since it began on September 13, 2014. The fire is currently 68% contained, and the cause of the fire is arson. Just a few days ago, (Sept. 23) the fire was only 38% contained so progress on extinguishing it continues. Over 7,700 personnel are battling this fire. A Pacific system came through the fire area yesterday (9/25) bringing 0.6-0.9 inches of rain. The observed fire activity was minimal with smoldering in interior pockets of the heavier fuels. A low pressure system will become the dominate feature today (9/26) ...

Agricultural fires blaze in Borneo

2014-09-26

The skies over Indonesian Borneo were filled with the smoke from hundreds of fires set deliberately to clear farmland. A shroud of thick, gray smoke hung over the area when the Aqua satellite captured this image on September 25, 2014. The Moderate Resolution Imaging Spectroradiometer (MODIS) instrument aboard the Aqua satellite detected dozens of fires (locations outlined in red) across the entire region from Central Borneo to South Borneo and even on East Laut Island. Widespread burning in lowland forests on Borneo is an annual, manmade occurrence. People use fires ...

New molecule found in space connotes life origins

2014-09-26

Hunting from a distance of 27,000 light years, astronomers have discovered an unusual carbon-based molecule – one with a branched structure – contained within a giant gas cloud in interstellar space. Like finding a molecular needle in a cosmic haystack, astronomers have detected radio waves emitted by isopropyl cyanide. The discovery suggests that the complex molecules needed for life may have their origins in interstellar space. Using the Atacama Large Millimeter/submillimeter Array, known as the ALMA Observatory, a group of radio telescopes funded partially through ...

Scientists discover new poison dart frog species in Donoso, Panama

2014-09-26

A bright orange poison dart frog with a unique call was discovered in Donoso, Panama, and described by researchers from the Smithsonian Tropical Research Institute and the Universidad Autónoma de Chiriquí in Panama, and the Universidad de los Andes in Colombia. In the species description published this week in Zootaxa, it was named Andinobates geminisae for Geminis Vargas, "the beloved wife of [coauthor] Marcos Ponce, for her unconditional support of his studies of Panamanian herpetology." Every new species name is based on a representative specimen. The specimen for ...

Many patients excluded from clinical trials due to prior cancer, UTSW study finds

2014-09-26

DALLAS – Sept. 26, 2014 – Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50 lung cancer clinical trials examined, more than 80 percent excluded patients with prior cancer from participating, according to the study published in the Journal of the National Cancer Institute. The exclusion criterion was even applied in more than two-thirds of trials in which survival was not the primary endpoint. "Our research demonstrates ...

Preference for built-up habitats could explain rapid spread of the tree bumblebee in UK

2014-09-26

The strikingly rapid spread of the Tree Bumblebee in Britain could be occurring because the bees readily live alongside humans in towns and villages – according to research from the University of East Anglia. A new study published today shows that Tree Bumblebees are associated with built-up areas and that these areas form a large part of their habitat use. These markedly different habitat and foraging preferences set this species apart from other common British bumblebee species – which could explain how Tree Bumblebees have managed to colonise much of the UK while ...

Policies of NIH, other funders, have improved data-sharing by life-science investigators

2014-09-26

Policies put into place by major funding agencies like the National Institutes of Health (NIH), and to a lesser extent by scientific journals, appear to be meeting the goal of increasing the sharing of scientific resources among life science investigators. As reported in the open-access journal PLOS ONE, 65 percent of surveyed investigators at major U.S. research institutions believed that NIH policies instituted in recent years had markedly improved the sharing of scientific data. But the survey also identified some unexpected problems, including the number of researchers ...

The scarring effects of primary-grade retention?

2014-09-26

An article released by Social Forces titled, "The Scarring Effects of Primary-Grade Retention? A Study of Cumulative Advantage in the Educational Career" by Megan Andrew explores the effect of scarring in the educational career in the case of primary-grade retention. Just as is the case for labor-market careers, events early in the educational career can leave lasting scars. Through the study, Andrew finds that primary-grade retention has lasting effects on educational attainments well after a student is initially retained: Retaining a child in early primary school reduces ...

Afatinib improves progression-free survival in head and neck cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: